Genetic Information
Gene & Transcript Details
| ID | Status | Details |
|---|---|---|
| NM_000051.3 | RefSeq Select | 13147 nt | 386–9556 |
| NM_000051.4 | MANE Select | 12915 nt | 151–9321 |
Variant Details
Clinical & Population Data
Population Frequency
gnomADClinVar
OpenVariant summary: ATM c.1158delG (p.Lys387ArgfsX3) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (c.1339C>T, p.Arg447X; c.1564_1565delGA, p.Glu522fsX43; c.2502dupA, p.Val835fsX7). The variant was absent in 251274 control chromosomes (gnomAD). The variant, c.1158delG, has been reported in the literature in multiple individuals affected with Ataxia-Telangiectasia (Izatt_1999, Thompson_2005, Nahas_2009, Schon_2019). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three ClinVar submissions from other clinical diagnostic laboratories (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
The c.1158delG pathogenic mutation, located in coding exon 8 of the ATM gene, results from a deletion of one nucleotide at nucleotide position 1158, causing a translational frameshift with a predicted alternate stop codon (p.K387Rfs*3). This mutation has been identified in trans with another ATM mutation in patients with ataxia-telangiectasia (Izatt L et al. Eur. J. Hum. Genet., 1999 Apr;7:310-20; Schon K et al. Ann Neurol, 2019 02;85:170-180). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
This sequence change creates a premature translational stop signal (p.Lys387Argfs*3) in the ATM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ATM are known to be pathogenic (PMID: 23807571, 25614872). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with ataxia-telangiectasia (PMID: 10234507). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 141887). For these reasons, this variant has been classified as Pathogenic.
"This variant has been reported in ClinVar as Pathogenic (8 clinical laboratories) and as Pathogenic by ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Variant Curation Expert Panel, ClinGen expert panel."
COSMIC Somatic Evidence
Open
Functional Impact & Domains
Functional Domain
Error in OpenAI Consolidation. OncoKB: ATMK387Rfs*3ATMK387Rfs*3SomaticNCBI Gene:472|Show additional gene information Variant OverviewATM, a kinase involved in the DNA damage response, is mutated in various solid and hematologic malignancies.The ATM K387Rfs*3 is a truncating mutation in a tumor suppressor gene, and therefore is likely oncogenic.Hide mutation effect description The mutation effect description for truncating mutations in ATM is: ATM truncating mutations can produce several forms of C-terminally truncated ATM proteins. When found in the germline, these mutations result in ataxia-telangiectasia syndrome, which increases cancer predisposition, including a 20% to 30% lifetime risk of lymphoid, gastric, breast, central nervous system, skin, and other cancers (PMID: 27413114). Deletion of ATM in mouse models and cell lines demonstrates that it is oncogenic as measured by decreased DNA repair efficiency and increased cellular motility (PMID: 30553448, 30348496). JAX-CKB: No results found
Click on previews to view full database entries. External databases may require institutional access.
Computational Analysis
Pathogenicity Predictions
SpliceAISpliceAI Scores
Window: ±500bp| Effect Type | Score | Position |
|---|---|---|
| Acceptor Loss (AL) | 0.01 | -478 bp |
| Donor Loss (DL) | 0.0 | 380 bp |
| Acceptor Gain (AG) | 0.11 | -90 bp |
| Donor Gain (DG) | 0.07 | 79 bp |
VCEP Guidelines
Applied ACMG/AMP Criteria (VCEP Specific)
PVS1 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
PS3 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
PM2 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
PP5 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)